Novel Chemistry Allows Conjugation of Largazole Analogs to Receptor Ligands or Other Cytotoxic Agents Fort Collins, CO, January 21, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,538,534 covering Cetya’s novel ability to conjugate receptor ligands or other cytotoxic agents to its unique HDAC inhibitors, creating targeted and dual-acting anticancer compounds. […]

 $1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle cell disease   Fort Collins, CO, September 17, 2019 – Cetya Therapeutics, Inc. announces the award of a $1,000,000 Phase II STTR grant from the National Heart, Lung and Blood Institute of NIH to support the in vivo assessment of its […]